CompletedNCT01609153
Olanzapine and Amisulpride Together or Separately for Schizophrenia
About this title
Read the official source — NCT01609153Medication studyAges 18–65Germany
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Aachen and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: June 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 328
- Sponsor
- Heinrich-Heine University, Duesseldorf
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Germany
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01609153
- Official title
Show the full official title
A Randomized Double-blind Controlled Trial to Assess the Benefits of Olanzapine and Amisulpride Combination Treatment in Acutely Ill Schizophrenia Patients. - COMBINE
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Aachen · Alzey · Andernach
17 more locations
- Augsburg
- Berlin
- Cologne
- Dortmund
- Düsseldorf
- Göttingen
- Groß-Umstadt
- Günzburg
- Hanover
- Heidelberg
- Langenfeld
- Leipzig
- Mainz
- Mannheim
- München
- Regensburg
- Würzburg
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Heinrich-Heine University, Duesseldorf, a university.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine, Amisulpride and Olanzapine and Amisulpride.
Who was this study for?
Listed age limits: 18 years to 65 years.
